In-Vivo Evaluation Of Different Formulation On Relief Of Asthma And Chronic Obstructive Pulmonary Disease (Copd) Using Levo Salbutamol
The effect of monotherapy with racemic salbutamol and levosalbutamol on symptoms, quality of life, and pulmonary function has been assessed and compared in mild persistent asthma. A rabbits were fed with Pulsatile tablets of Levosalbutamol (optimized formulation), Group B fed with Marketed drug with equivalent dose to animal body weight. Blood samples (approximately 0.5ml) were obtained with syringes by marginal ear vein at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 20 and 24h post dose. During collection, blood sample has been mixed thoroughly with heparin in order to prevent blood clotting. The average tmax values were found to be 4.0 ± 0.14h, and 8.02 ±0.12h for Marketed drug Levosalbutamol and pulsatile drug respectively. Marketed drug formulation showed low value of tmax (2h) which indicates faster absorption of the drug as compared to pulsatile drug formulation. that Marketed drug Levosalbutamol showed pattern of drug absorption and pulsatile drug formulation showed a lag time of 3 hours before finally showing maximum concentration (Cmax) at 8 hours, which correlated with the in-vitro release (8 hours) One way analysis of variance (ANOVA) using Dunnett multiple comparison test on computer program Graph pad Instat 3 was used, the differences were considered significant at p value equal or less than 0.05( p≤ 0.05).